Di Gu

Phase 1 Dose-Escalation Study of the Rapid-Clearance Radioligand [ 177 Lu]Lu-P17-087 in Metastatic Castration-Resistant Prostate Cancer: Dosimetry, Safety, and Preliminary Efficacy

Given the rapid systemic clearance and favorable kinetic profile of the novel DOTA(GA)2-conjugated ligand [177Lu]Lu-P17-087, this phase 1 study aimed to systematically evaluate the safety, pharmacokinetics, dosimetry, and preliminary antitumor activity of escalating therapeutic a...